Number of cancer survivors with functional limitations doubled in 20 years
The 70% prevalence of functional limitation among survivors in 2018 is nearly twice that of the general population.
Experts debate reducing ASCT for multiple myeloma
Overall survival following multidrug regimens and transplant are on par, raising questions about the best frontline therapy for multiple myeloma...
Motixafortide may improve MM outcomes
A new drug approval for motixafortide is currently under review by the Food and Drug Administration.
From Beirut to frontline hematology research
A young Lebanese-American physician scientist keeps ‘smoldering’ myeloma in his sights and a sick relative in mind.
AFib risk with cancer drugs underestimated
Many cancer therapies increase the risk of atrial fibrillation, but this is underreported in clinical trials.
Erythema extent predicts death in cutaneous GVHD
Study: Extent of skin erythema correlates with deaths from graft-versus-host disease in blood cancer patients after stem cell transplants.
Blenrep for multiple myeloma withdrawn from U.S. market
As requested by the U.S. Food and Drug Administration, the multiple myeloma drug blenrep is being taken off the market after disappointing results...
CAR T-cell therapy neurotoxicity linked to NfL elevations
Even prior to CAR T-cell therapy, patients developing related neurotoxic complications show elevated markers of neuronal injury.
Pivotal trials in blood cancers don’t mirror patient populations
“The results from this study should lead to questions about the generalizability of drug safety and efficacy in populations we serve as medical...
Agent Orange Exposure, Transformation From MGUS to Multiple Myeloma, and Outcomes in Veterans
This study explored variation in survival related to Agent Orange exposure, transformation from MGUS to multiple myeloma, and survival as a...